Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: It is unknown whether insulin therapy can delay or prevent diabetes in nondiabetic relatives of patients with diabetes. METHODS: In a randomized, controlled, nonblinded clinical trial, we screened 84,228 first-degree and second-degree relatives of patients with diabetes for islet-cell antibodies; 3152 tested positive; 2103 of the 3152 underwent genetic, immunologic, and metabolic staging to quantify their risk; 372 of the 2103 had a projected five-year risk of more than 50 percent; 339 of the 372 (median age, 11.2 years) were randomly assigned to undergo either close observation or an intervention that consisted of low-dose subcutaneous ultralente insulin, administered twice daily for a total dose of 0.25 unit per kilogram of body weight per day, plus annual four-day continuous intravenous infusions of insulin. Oral glucose-tolerance tests were performed every six months. Median follow-up was 3.7 years. The primary end point was a diagnosis of diabetes. RESULTS: Diabetes was diagnosed in 69 subjects in the intervention group and 70 subjects in the observation group. The annualized rate of progression to diabetes was 15.1 percent in the intervention group and 14.6 percent in the observation group. The cumulative incidence of diabetes was similar in the two groups (relative risk in the intervention group as compared with the observation group, 0.96). Most subjects in whom diabetes developed were asymptomatic. Progression to diabetes occurred at a faster rate among subjects with abnormal base-line glucose tolerance (22 percent per year) than among those with normal base-line glucose tolerance (10 percent per year, P<0.001). There were no episodes of severe hypoglycemia. The incidence of chemical hypoglycemia, assessed without ascertainment bias, was similar in the two groups. CONCLUSIONS: In persons at high risk for diabetes, insulin at the dosage used in this study does not delay or prevent type 1 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but subgroup analyses suggested a benefit of oral insulin in individuals with the highest titres of insulin auto-antibodies.142,143”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“The Diabetes Prevention Trial—Type 1, tested whether oral or parental insulin prevented the development of type 1 diabetes in people who were autoantibody positive. Neither approach reduced diabetes development,”
From Type 1 diabetes (2018) · cites this paper as [142]
In the citing paper
“If one islet autoantibody is found, the test should be repeated and the other autoantibodies should be assayed because the risk of type 1 diabetes increases if two or more autoantibodies are positive (443).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [443]
In the citing paper
“Subcutaneously or intranasally delivered insulin was found to have no preventive effects.39,48”
From The future of type 1 diabetes therapy (2025) · cites this paper as [48]
In the citing paper
“Risk can be assessed by islet cell autoantibodies alone, without the need for evaluating endogenous insulin reserves, as was done for the U.S. DPT-1 trial (306).”
From Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (2011) · cites this paper as [306]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
The Pathogenesis of Insulin-Dependent Diabetes Mellitus
Epstein, F. H., Atkinson, M. A., & Maclaren, N. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411243312107 · Cited by 1,078
Verge, C. F., Stenger, D., Bonifacio, E., Colman, P. G., Pilcher, C., Bingley, P. J., & Eisenbarth, G. S. (1998) · Diabetes · doi:10.2337/diabetes.47.12.1857 · Cited by 420
Cognitive Deficits in Adolescents Who Developed Diabetes Early in Life
Ryan, C., Vega, A., & Drash, A. (1985) · Pediatrics · doi:10.1542/peds.75.5.921 · Cited by 413
Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy
Atkinson, M. A., Maclaren, N. K., & Luchetta, R. (1990) · Diabetes · doi:10.2337/diab.39.8.933 · Cited by 299
Insulin prophylaxis in individuals at high risk of type 1 diabetes
Keller, R. J., Jackson, R. A., Eisenbarth, G. S., & Eisenbarth, G. (1993) · The Lancet · doi:10.1016/0140-6736(93)91215-8 · Cited by 298
Pugliese, A., Gianani, R., Moromisato, R., Awdeh, Z. L., Alper, C. A., Erlich, H. A., Jackson, R. A., & Eisenbarth, G. S. (1995) · Diabetes · doi:10.2337/diab.44.6.608 · Cited by 207
Gotfredsen, C. F., Buschard, K., & Frandsen, E. K. (1985) · Diabetologia · doi:10.1007/bf00703140 · Cited by 205
Vardi, P., Dib, S. A., Tuttleman, M., Connelly, J. E., Grinbergs, M., Radizabeh, A., Riley, W. J., Maclaren, N. K., Eisenbarth, G. S., & Soeldner, J. S. (1987) · Diabetes · doi:10.2337/diab.36.11.1286 · Cited by 192
Attentional Functioning in Children and Adolescents With IDDM
Rovet, J., & Alvarez, M. (1997) · Diabetes Care · doi:10.2337/diacare.20.5.803 · Cited by 153
Cited by
Items 601–700 of 832
Lessons for human diabetes from experimental mouse models
Kulkarni, R., & Zisman, A. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0041-x · Cited by 5
Prädiktion und Prävention des Typ-1-Diabetes
Schmid, S., & Ziegler, A. (2001) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2001-14096 · Cited by 4
Lernmark, Å. (2013) · Diabetologia · doi:10.1007/s00125-013-3041-7 · Cited by 4
Can the current healthcare delivery model cope with advanced type 2 diabetes?
Hodish, I. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.01.005 · Cited by 4
Secondary measures of immunologic efficacy in clinical trials
Peakman, M., & Roep, B. O. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000235321.01047.5d · Cited by 4
Limitations in Immunotherapy with CD3 Antibodies: Comment on the Article by Drs. Chatenoud and Bach
Bresson, D., & von Herrath, M. (2005) · The Review of Diabetic Studies · doi:10.1900/rds.2005.2.187 · Cited by 4
Ludvigsson, J., & Noman, S. M. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70093 · Cited by 3
Epidemiology and Pathogenesis of Type 1 Diabetes
Stene, L. C., & Lernmark, Å. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_2 · Cited by 4
Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges
Bhagi, M., Kaur, J., Dhar, A., & Bhat, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010287216240324050651 · Cited by 4
Prevention of Type 1 Diabetes Mellitus
Pozzilli, P., & Guglielmi, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_49 · Cited by 3
Zhao, L. P., Papadopoulos, G. K., Skyler, J. S., Pugliese, A., Parikh, H. M., Kwok, W. W., Lybrand, T. P., Bondinas, G. P., Moustakas, A. K., Wang, R., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06274-6 · Cited by 4
Immunotherapy for type 1 diabetes
Sann, K. M., Rahman, M. A., & Thu, M. M. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.37 · Cited by 5
Insulin sensitizer prevents and ameliorates experimental type 1 diabetes
Valitsky, M., Hoffman, A., Unterman, T. G., & Bar‐Tana, J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2016 · Cited by 4
Latent Autoimmune Diabetes in Adults
Naik, R. G., & Palmer, J. P. (2007) · CRC Press eBooks · doi:10.3109/9780849326233-3 · Cited by 3
Preventing type 1 diabetes development and preserving beta-cell function
Mastrandrea, L. D., & Quattrin, T. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000746 · Cited by 3
Prévenir et guérir le diabète insulino-dépendant
Bach, J. (2003) · Pathologie Biologie · doi:10.1016/s0369-8114(02)00363-2 · Cited by 3
Clinique et diagnostic du diabète de l'enfant
Bouhours‐Nouet, N., & Coutant, R. (2005) · EMC - Pédiatrie · doi:10.1016/j.emcped.2005.06.001 · Cited by 11
Of Bugs and Men: Antigen-Fortified Lactoccoccus lactis for Type 1 Diabetes Immunotherapy
Mallone, R., & Čulina, S. (2014) · Diabetes · doi:10.2337/db14-0587 · Cited by 5
Type 1 diabetes: New horizons in prediction and prevention
Razack, B. N. N., & Wherrett, D. K. (2005) · Paediatrics & Child Health · doi:10.1093/pch/10.1.35 · Cited by 3
Skyler, J. S. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_15-1 · Cited by 4
Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents
Holder, M., Kapellen, T. M., Ziegler, R., Bürger-Büsing, J., Danne, T., Dost, A., Holl, R. W., Holterhus, P., Karges, B., Kordonouri, O., et al. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3388 · Cited by 6
Insulin auto-immunity: implications for the prevention of Type 1 diabetes mellitus
Wicklow, B. A., & Polychronakos, C. (2008) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.5.1.55 · Cited by 3
Prévention du diabète de type 1. Où en sommes-nous? Que dire et proposer aux familles?
Vialettes, B., Valéro, R., Mattei, C., & Nervi, S. (2003) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70082-4 · Cited by 3
The role of the physician–scientist in bridging basic and clinical research in type 1 diabetes
Rigby, M. R. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833759d2 · Cited by 3
Wilkin, T. J. (2007) · Diabetologia · doi:10.1007/s00125-007-0829-3 · Cited by 3
Growing pains in the pursuit of diabetes prevention
Wang, P. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15818-2 · Cited by 3
Prevention of Autoimmune Disease: Type 1 Diabetes as a Paradigm
Harrison, L. C. (2006) · Elsevier eBooks · doi:10.1016/b978-012595961-2/50078-0 · Cited by 3
Norris, A. W., & Wolfsdorf, J. I. (2009) · Wiley eBooks · doi:10.1002/9781444316728.ch18 · Cited by 3
Norris, A. W., & Wolfsdorf, J. I. (2005) · Wiley eBooks · doi:10.1002/9780470987117.ch21 · Cited by 15
Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us
Galderisi, A. (2023) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.126360 · Cited by 2
Perspectives on prevention of type 1 diabetes and heterogeneities
Stene, L. C. (2025) · Diabetologia · doi:10.1007/s00125-025-06512-5 · Cited by 3
Are We Ready With Prevention for Type 1 Diabetes?
Maines, E., Franceschi, R., Candia, F. D., & Mozzillo, E. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70101 · Cited by 3
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01048-x · Cited by 2
First test effect in intravenous glucose tolerance testing
Ismail, H. M., White, K. S., Krischer, J. P., Chase, H. P., Cuthbertson, D. D., Palmer, J. P., & DPT-1 Study Group (2013) · Pediatric Diabetes · doi:10.1111/pedi.12064 · Cited by 2
Self-citationDiagnóstico y manejo del paciente adulto con diabetes tipo1A al inicio de la enfermedad
Serra‐Planas, E., Guanyabens, E., & Aguilera, E. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.01.001 · Cited by 6
Chapter 5 The Pathogenesis of Type 1 Diabetes
Barker, J. M. (2008) · Technical report · doi:10.1016/s1571-5078(07)00205-x · Cited by 3
Prevention of β-Cell Destruction in Autoimmune Diabetes: Current Approaches and Future Prospects
Sedimbi, S. K., & Sanjeevi, C. B. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_26 · Cited by 2
Traitement du diabète de l'enfant et de l'adolescent
Boileau, P., Merle, B., & Bougneres, P. F. (2005) · EMC - Pédiatrie · doi:10.1016/j.emcped.2005.01.001 · Cited by 5
Perspective: Rethink the immune connection
Greenbaum, C. J. (2012) · Nature · doi:10.1038/485s9a · Cited by 2
Acceleration of autoimmune diabetes in Rheb-congenic NOD mice with β-cell-specific mTORC1 activation
Sasaki, H., Yasuda, H., Moriyama, H., Nakamura, A., Shimizu, M., Arai, T., Nagata, M., Hara, K., & Yokono, K. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.026 · Cited by 2
Immunology of Type I Diabetes: The Journey from Animal Models to Human Therapeutics
Upadhyaya, S. K. (2013) · Apollo Medicine · doi:10.1016/j.apme.2013.05.008 · Cited by 2
Network-based methods to identify highly discriminating subsets of biomarkers
Sajjadi, S. J., Qian, X., & Zeng, B. (2012) · IEEE International Workshop on Genomic Signal Processing and Statistics · doi:10.1109/gensips.2012.6507748 · Cited by 2
Katahira, M., Hanakita, M., Ito, T., Suzuki, M., & Segawa, S. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.017 · Cited by 2
The epidemiology and prevention of diabetes mellitus
Unwin, N. C., & Zimmet, P. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199218707.003.0063 · Cited by 4
Étiologie et physiopathologie du diabète de type 1
Dubois‐Laforgue, D. (2007) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(07)46585-4 · Cited by 7
Treatment of Type 1 Diabetes Mellitus in Adults
Retnakaran, R. R., & Zinman, B. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00045-9 · Cited by 2
Islet Transplants for Diabetes: The Edmonton Protocol
Senior, P. A., & Shapiro, A. M. J. (2007) · Elsevier eBooks · doi:10.1016/b978-012369415-7/50006-5 · Cited by 4
Dynamic Inspection of Latent Variables in State-Space Systems
Feng, T., Qian, X., Liu, K., & Huang, S. (2019) · IEEE Transactions on Automation Science and Engineering · doi:10.1109/tase.2018.2884149 · Cited by 2
Hummel, M., & Achenbach, P. (2015) · Der Internist · doi:10.1007/s00108-014-3626-3 · Cited by 2
Type 1 Diabetes Mellitus: Epidemiology, Genetics, Pathogenesis, and Clinical Manifestations
Ali, O. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_12-1 · Cited by 2
Burgess, J. G. (2014) · ASM Press eBooks · doi:10.1128/9781555815714.ch28 · Cited by 2
Genetic Markers, Serological Auto Antibodies and Prediction of Type 1 Diabetes
Fakhfakh, R. (2011) · InTech eBooks · doi:10.5772/23889 · Cited by 2
Gupta, M., Ludvigsson, J., & SANJEEVI, C. B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1337.023 · Cited by 2
Management of Type 2 Diabetes Mellitus: Is It Time for a Paradigm Shift?
Wyne, K. L. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.251 · Cited by 2
Epidemiology of Acute Complications in Youth: Diabetic Ketoacidosis and Hypoglycemia
Rewers, A. (2008) · CRC Press eBooks · doi:10.3109/9781420047981-17 · Cited by 4
Lee, S., Kwak, J., Kim, S. H., Yun, J., Cho, J., Kim, K., Hwang, D.-Y., & Jung, Y.-S. (2018) · Laboratory Animal Research · doi:10.5625/lar.2018.34.4.232 · Cited by 2
Microcontroller-Based Detection of Diabetes and Ketosis State Using Breath Sensors
Renumadhavi, C. H., Jamuna, N., Chandana, A. N., Balamurali, V., Gupta, P. K., Sheriff, R. S., Lokur, A. V., Kallur, R., & Sindhu, R. (2020) · Advances in intelligent systems and computing · doi:10.1007/978-981-15-2740-1_1 · Cited by 2
Atkinson, M. A., & Skyler, J. S. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1028-7_4 · Cited by 2
Therapy of Type 1 Diabetes Mellitus
Cohan, P., & Peters, A. L. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_43 · Cited by 3
Aetiology of Type 1 Diabetes Mellitus ‐ Genetics, Autoimmunity and Trigger Factors
Marcovecchio, M. L., Dunger, D. B., Peakman, M., & Taylor, K. W. (2007) · Wiley eBooks · doi:10.1002/9780470692271.ch3 · Cited by 3
Immunotherapy of Type-1 Diabetes: Immunoprevention and Immunoreversal
Waldron-Lynch, F., & Herold, K. C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-478-4_18 · Cited by 2
Chatenoud, L., & Bach, J. (2005) · The Review of Diabetic Studies · doi:10.1900/rds.2005.2.116 · Cited by 2
Chatenoud, L. (2007) · médecine/sciences · doi:10.1051/medsci/2007232167 · Cited by 3
Chakkera, H. A., Pham, P. T., Pomeroy, J. J., Weil, E. J., & Knowler, W. C. (2013) · Diabetes Care · doi:10.2337/dc13-1656 · Cited by 2
In Pursuit of Type 1 Diabetes Prevention
Marks, J. B. (2002) · Clinical Diabetes · doi:10.2337/diaclin.20.4.168 · Cited by 2
Primary prevention of type 1A diabetes: are we there yet?
Barker, J. M., & Eisenbarth, G. S. (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00256.x · Cited by 2
Antigen-based immune modulation: DNA vectors and beyond
Bot, A. I., Phillips, W. J., & von Herrath, M. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.8.929 · Cited by 3
Stopping Diabetes in its Tracks: Autologous Non-Myeloablative Stem Cell Transplantation
Fousteri, G., Hayek, A., & von Herrath, M. (2007) · Regenerative Medicine · doi:10.2217/17460751.2.5.845 · Cited by 2
Adiponectin and immune tolerance in type 1 diabetes
Pang, T. (2011) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 3
Gale, E. A., & Bingley, P. J. (2004) · CRC Press eBooks · doi:10.1201/9780203021941-24 · Cited by 2
Skyler, J. S. (2010) · Wiley eBooks · doi:10.1002/9780470682807.ch4 · Cited by 2
Therapy of Type 1 Diabetes Mellitus
Omura, E., Cohan, P., & Peters, A. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_43-2 · Cited by 1
Two DRB3 residues predictively associate with the progression to type 1 diabetes among DR3 carriers
Zhao, L. P., Papadopoulos, G. K., Skyler, J. S., Kwok, W. W., Bondinas, G. P., Moustakas, A. K., Wang, R., Pyo, C., Nelson, W. C., Geraghty, D. E., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.184348 · Cited by 4
Pharmacotherapy of type 1 diabetes – part 3: tomorrow
Rendell, M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2468906 · Cited by 1
Zhao, L. P., Papadopoulos, G. K., McFarland, B. J., Skyler, J. S., Parikh, H. M., Kwok, W. W., Lybrand, T. P., Bondinas, G. P., Moustakas, A. K., Wang, R., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06520-5 · Cited by 2
Lessons from Prediction and Prevention of Type 1 Diabetes
Speake, C., Lacy‐Hulbert, A., Lord, J. D., & Greenbaum, C. J. (2025) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaf175 · Cited by 1
How Should an IBD Prevention Trial Be Designed?
Goetgebuer, R., Ungaro, R. C., Feagan, B. G., Jairath, V., Colombel, J., & D’Haens, G. (2025) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaf212 · Cited by 1
Moscovitz, K., Bhavsar, D., & Tremlett, H. L. (2026) · Journal of Autoimmunity · doi:10.1016/j.jaut.2026.103526 · Cited by 1
Longitudinal dynamics of fasting plasma uridine in the preclinical stage of type 1 diabetes
Xiong, Q., Jang, C., Wang, K., Fu, L. L., Ding, L. H., Wang, Z. V., Wang, P., & Deng, Y. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag059 · Cited by 1
Sims, E. K., Skyler, J. S., Jacobsen, L. M., Ismail, H. M., REDONDO, M. J., Nathan, B. M., Cuthbertson, D., & Sosenko, J. M. (2026) · Diabetes Care · doi:10.2337/dci26-0022 · Cited by 1
Ngcobo, N. N., & Sibiya, N. H. (2026) · Pathophysiology · doi:10.3390/pathophysiology33030048 · Cited by 1
Der latent autoimmune Diabetes im Erwachsenenalter (LADA): Eine Sonderform des Diabetes?
Schloot, N. C. (2008) · Der Diabetologe · doi:10.1007/s11428-008-0280-1 · Cited by 1
Changing horizons: approaches to diabetes care, current and future
Goldfine, A. B. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328095194f · Cited by 1
Treatment of Type 1 Diabetes Mellitus in Adults
Retnakaran, R. R., & Zinman, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00044-5 · Cited by 1
Management of Diabetes Mellitus in Children
Wolfsdorf, J. I., & Botero, D. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00049-6 · Cited by 1
The Present and Future of Type 1 Diabetes Prevention: Teplizumab and Immunomodulators
Sohn, H., Kim, S., & Yoon, J.-H. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.4.210 · Cited by 1
History of alternative preventive therapies for type 1 diabetes mellitus
Сергеевна, Х. Т., Миняйлова, Н. Н., Будникова, О. В., & Владимировна, В. А. (2025) · Кубанский научный медицинский вестник · doi:10.25207/1608-6228-2025-32-1-87-98 · Cited by 1
Humoral Immunity in Type 1 Diabetes Mellitus
Pietropaolo, M., & Sperling, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-444-56378-1.00048-4 · Cited by 1
The expanding horizons of Pediatric Diabetes
Sperling, M. A. (2004) · Pediatric Diabetes · doi:10.1111/j.1399-543x.2004.00042.x · Cited by 1
Inmunoterapia en diabetes mellitus tipo 1. ¿Quo vadis?
Fernández-Balsells, M., Sojo-Vega, L., & Ricart, W. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.08.001 · Cited by 1
Prevention of Autoimmune Disease
Harrison, L. C., & Wentworth, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-384929-8.00079-4 · Cited by 1
Are we aiming to miss in translational autoimmunity treatments?
Vaitaitis, G. M., & Wagner, D. H. (2018) · F1000Research · doi:10.12688/f1000research.16894.1 · Cited by 1
Emerging Biological and Molecular Therapies in Autoimmune Disease
Chatenoud, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00072-5 · Cited by 1
Immunotherapy for Autoimmune Diseases
Mali, A. V., Sawant, A., Mahadik, A., & Nair, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-9038-2_4 · Cited by 1
Type 1 diabetes mellitus in children
Klinika za pedijatriju, K. R., Severinski, S., Ahel, I. B., Klinika za pedijatriju, K. R., Božinović, I., & Medicinski fakultet Sveučilišta u Rijeci, R. (2016) · Medicina · doi:10.21860/medflum2016_4ser · Cited by 1
Feature ranking based on synergy networks to identify prognostic markers in DPT-1
Adl, A. A., Qian, X., Xu, P., Vehik, K., & Krischer, J. P. (2012) · IEEE International Workshop on Genomic Signal Processing and Statistics · doi:10.1109/gensips.2012.6507728 · Cited by 1
Precision medicine to manage chronic immune-related conditions
Gibson, D. S., Egan, P., Guo, G., Kelly, C., McClean, P. L., McGilligan, V., McAllister, R., Matchett, K. B., Martin, C. A., Murray, E. K., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824390-9.00009-8 · Cited by 1
Prediction of autoimmune diseases: From bench to bedside
Vivas, Á. J., & Tobón, G. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824390-9.00001-3 · Cited by 1
Immunology of type 1 diabetes mellitus
Peakman, M. (2011) · doi:10.1093/med/9780199235292.003.1319 · Cited by 2
Type 1 Diabetes Mellitus: Epidemiology, Genetics, Pathogenesis, and Clinical Manifestations
Ali, O. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_12 · Cited by 2
Metadata
- Authors
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Affiliations
- University of Miami (US)
- Corresponding author
- Diabetes Prevention Trial–Type 1 Diabetes Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-30
- Volume
- 346
- Issue
- 22
- Pages
- 1685-1691
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W614574849
- Cited by
- 836
- References
- 30
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 24 · 2023: 21 · 2022: 20 · 2021: 32 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 27 · 2016: 26 · 2015: 34 · 2014: 30 · 2013: 38 · 2012: 42
- FWCI
- 28.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK117009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, insulin therapy, diabetes prevention, relatives of diabetic patients, islet cell antibodies, ultralente insulin, continuous intravenous insulin infusion, glucose tolerance, hypoglycemia, disease progression
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Diabetes Mellitus, Type 1, Family, Female, Glucose Tolerance Test, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Islets of Langerhans, Male, Middle Aged, Risk Factors, Treatment Failure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.